About Us

Shuttle Pharmaceuticals is developing novel therapies that are designed to increase cancer cure rates and improve the outcomes of patients receiving radiation therapy.

Pioneering Innovative Therapies

We are pioneering innovative therapies that target cancer cells, protect healthy tissue, and harness the body’s innate immune response. Our mission is to enhance the power of radiation therapy (RT) while minimizing its side effects. By leveraging our proprietary technologies to develop breakthrough radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy.

Our diagnostics approach is to offer prognosis and guide treatment decisions, with the goal of providing clinicians and patients with a means of measuring the potential for success of RT for their cancer treatment.

Our Work. Our Purpose.

At Shuttle, our mission is to launch the next generation of radiation oncology treatments with the goal of curing cancer. With this goal, we are setting out to accomplish something that has never been done before. We acknowledge that this will not be an easy task and will require dedication, extreme effort, and expertise.

Through teamwork and strategic collaboration, we believe in our ability to make a meaningful difference. By pushing scientific boundaries and working together, we aim to improve the lives of millions impacted by cancer and bring hope to patients and families around the world.

Advancing Preclinical Drug Development

Shuttle Pharma Laboratories play a critical role in supporting preclinical drug development by cultivating cancer cells for use in cellular toxicity assays. Our process involves carefully plating cancer cells in specialized flasks with a tailored growth medium. After exposure to cytotoxic drugs, the cells are incubated and monitored as they form visible colonies under low-power microscopy. By comparing treated cells to non-treated controls, we assess drug efficacy and drive progress in cancer therapy research.
Shuttle Pharma Laboratories
Shuttle Pharma Laboratories
Shuttle Pharma Laboratories
A technician prepares to plate cancer cells in specialized flasks with specialized medium at Shuttle Pharma Laboratories.
A technician prepares to plate cancer cells in specialized flasks with specialized medium at Shuttle Pharma Laboratories.
Incubated cancer cell colonies at Shuttle Pharma Laboratories.
Plated cancer cells in specialized flasks with specialized medium.
Following exposure to cytotoxic drugs, cells are incubated to grow into colonies easily visible using low power microscopy.
Plated cancer cells. Shuttle Pharma Laboratories.
Dr. Anatoly Dritschilo views cancer cell colonies using low power microscopy.
Viewing cancer cell colonies using low power microscopy at Shuttle Pharma Laboratories.
Shuttle Pharma Founder & CEO, Anatoly Dritschilo, M.D., at Shuttle Pharma Laboratories.

Innovation Through Strategic Collaboration

We have established a longstanding, strategic collaboration with Georgetown University, working closely with scientists from the Georgetown University School of Medicine to push the boundaries of research in radiation physics, radiation biology, and immunology.

Radiation therapy unit at Georgetown University School of Medicine.
Radiation therapy unit at Georgetown University School of Medicine.
View of a radiation therapy treatment plan. Georgetown University School of Medicine.
CyberKnife robotic radiation therapy unit at Georgetown University School of Medicine.
CyberKnife robotic radiation therapy unit at Georgetown University School of Medicine.
Portable CT scanner at Georgetown University School of Medicine.

Dr. Alejandro Villagra, Associate Professor at Georgetown University and member of Shuttle’s Scientific Advisory Board, highlights the pioneering advancements taking place in the immunology laboratory, where cutting-edge research is driving new frontiers in cancer treatment.

Dr. Alejandro Villagra at Georgetown University School of Medicine immunology lab.
Dr. Alejandro Villagra and Dr. Anatoly Dritschilo at Georgetown University School of Medicine immunology lab.
Dr. Alejandro Villagra and Dr. Anatoly Dritschilo at Georgetown University School of Medicine immunology lab.
Dr. Alejandro Villagra and Dr. Anatoly Dritschilo at Georgetown University School of Medicine immunology lab.
Georgetown University School of Medicine immunology laboratory.
Georgetown University School of Medicine immunology laboratory.
Georgetown University School of Medicine immunology laboratory.
Georgetown University School of Medicine immunology lab.

Dr. Dalong Pang, Chief of the Radiation Physics Division and Director of the Radiation Physics Residency Program at MedStar Georgetown University Hospital, and Professor of Radiation Medicine at Georgetown University School of Medicine, showcases the use of atomic force microscopy to investigate DNA damage and repair mechanisms—providing crucial insights that fuel the development of next-generation therapies.

Dr. Dalong Pang, Chief of the Radiation Physics Division and Director of the Radiation Physics Residency Program at MedStar Georgetown University Hospital, and Professor of Radiation Medicine at Georgetown University School of Medicine.
Dr. Dalong Pang (with Dr. Anatoly Dritschilo) demonstrates how atomic force microscopy applications are used to study breaks in DNA.
Picture of an atomic force microscopy. Georgetown University School of Medicine.
Dr. Dalong Pang demonstrates how atomic force microscopy applications are used to study breaks in DNA.
Dr. Dalong Pang, Chief of the Radiation Physics Division and Director of the Radiation Physics Residency Program at MedStar Georgetown University Hospital, and Professor of Radiation Medicine at Georgetown University School of Medicine.
Dr. Dalong Pang with Dr. Anatoly Dritschilo at Georgetown University School of Medicine
Skip to content